Q32 Bio Inc. reports results for the quarter ended June 30 - Earnings Summary

Q32 Bio

05/08/2026 12:51

Q32 Bio Inc. QTTB.OQ reported a quarterly adjusted loss of 44 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -78 cents.  The mean expectation of five analysts for the quarter was for a loss of 54 cents per share. Wall Street expected results to range from -61 cents to -48 cents per share.
Reported revenue was zero​; analysts expected zero. 
Q32 Bio Inc.'s reported EPS for the quarter was a loss of 44 cents​.
The company reported a quarterly loss of $8.95 million.
Q32 Bio Inc. shares had risen by 26.8% this quarter and gained 386.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 7.1% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Q32 Bio Inc. is $38.00, about 57.5% above its last closing price of $16.16
This summary was machine generated from LSEG data August 5 at 11:51 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.54
-0.44
Beat
Mar. 31 2026 
-0.68
-0.54
Beat
Dec. 31 2025 
-0.86
3.65
Beat
Sep. 30 2025 
-1.19
-0.60
Beat